Proteasome inhibition improves diaphragm function in congestive heart failure rats

Hieronymus W.H. Van Hees, Yi Ping Li, Coen A.C. Ottenheijm, Bingwen Jin, Cindy J.C. Pigmans, Marianne Linkels, P. N.Richard Dekhuijzen, Leo M.A. Heunks

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

In congestive heart failure (CHF), diaphragm weakness is known to occur and is associated with myosin loss and activation of the ubiquitin-proteasome pathway. The effect of modulating proteasome activity on myosin loss and diaphragm function is unknown. The present study investigated the effect of in vivo proteasome inhibition on myosin loss and diaphragm function in CHF rats. Coronary artery ligation was used as an animal model for CHF. Sham-operated rats served as controls. Animals were treated with the proteasome inhibitor bortezomib (intravenously) or received saline (0.9%) injections. Force generating capacity, cross-bridge cycling kinetics, and myosin content were measured in diaphragm single fibers. Proteasome activity, caspase-3 activity, and MuRF-1 and MAFbx mRNA levels were determined in diaphragm homogenates. Proteasome activities in the diaphragm were significantly reduced by bortezomib. Bortezomib treatment significantly improved diaphragm single fiber force generating capacity (∼30-40%) and cross-bridge cycling kinetics (∼20%) in CHF. Myosin content was ∼30% higher in diaphragm fibers from bortezomib-treated CHF rats than saline. Caspase-3 activity was decreased in diaphragm homogenates from bortezomib-treated rats. CHF increased MuRF-1 and MAFbx mRNA expression in the diaphragm, and bortezomib treatment diminished this rise. The present study demonstrates that treatment with a clinically used proteasome inhibitor improves diaphragm function by restoring myosin content in CHF.

Original languageEnglish
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume294
Issue number6
DOIs
Publication statusPublished - 1 Jun 2008

Cite this

Van Hees, Hieronymus W.H. ; Li, Yi Ping ; Ottenheijm, Coen A.C. ; Jin, Bingwen ; Pigmans, Cindy J.C. ; Linkels, Marianne ; Dekhuijzen, P. N.Richard ; Heunks, Leo M.A. / Proteasome inhibition improves diaphragm function in congestive heart failure rats. In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 2008 ; Vol. 294, No. 6.
@article{df5b6172227849de9b0a3276ca86ee9b,
title = "Proteasome inhibition improves diaphragm function in congestive heart failure rats",
abstract = "In congestive heart failure (CHF), diaphragm weakness is known to occur and is associated with myosin loss and activation of the ubiquitin-proteasome pathway. The effect of modulating proteasome activity on myosin loss and diaphragm function is unknown. The present study investigated the effect of in vivo proteasome inhibition on myosin loss and diaphragm function in CHF rats. Coronary artery ligation was used as an animal model for CHF. Sham-operated rats served as controls. Animals were treated with the proteasome inhibitor bortezomib (intravenously) or received saline (0.9{\%}) injections. Force generating capacity, cross-bridge cycling kinetics, and myosin content were measured in diaphragm single fibers. Proteasome activity, caspase-3 activity, and MuRF-1 and MAFbx mRNA levels were determined in diaphragm homogenates. Proteasome activities in the diaphragm were significantly reduced by bortezomib. Bortezomib treatment significantly improved diaphragm single fiber force generating capacity (∼30-40{\%}) and cross-bridge cycling kinetics (∼20{\%}) in CHF. Myosin content was ∼30{\%} higher in diaphragm fibers from bortezomib-treated CHF rats than saline. Caspase-3 activity was decreased in diaphragm homogenates from bortezomib-treated rats. CHF increased MuRF-1 and MAFbx mRNA expression in the diaphragm, and bortezomib treatment diminished this rise. The present study demonstrates that treatment with a clinically used proteasome inhibitor improves diaphragm function by restoring myosin content in CHF.",
keywords = "Bortezomib, Myosin, Single fiber contractility",
author = "{Van Hees}, {Hieronymus W.H.} and Li, {Yi Ping} and Ottenheijm, {Coen A.C.} and Bingwen Jin and Pigmans, {Cindy J.C.} and Marianne Linkels and Dekhuijzen, {P. N.Richard} and Heunks, {Leo M.A.}",
year = "2008",
month = "6",
day = "1",
doi = "10.1152/ajplung.00035.2008",
language = "English",
volume = "294",
journal = "American Journal of Physiology. Lung Cellular and Molecular Physiology",
issn = "1040-0605",
publisher = "American Physiological Society",
number = "6",

}

Proteasome inhibition improves diaphragm function in congestive heart failure rats. / Van Hees, Hieronymus W.H.; Li, Yi Ping; Ottenheijm, Coen A.C.; Jin, Bingwen; Pigmans, Cindy J.C.; Linkels, Marianne; Dekhuijzen, P. N.Richard; Heunks, Leo M.A.

In: American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 294, No. 6, 01.06.2008.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Proteasome inhibition improves diaphragm function in congestive heart failure rats

AU - Van Hees, Hieronymus W.H.

AU - Li, Yi Ping

AU - Ottenheijm, Coen A.C.

AU - Jin, Bingwen

AU - Pigmans, Cindy J.C.

AU - Linkels, Marianne

AU - Dekhuijzen, P. N.Richard

AU - Heunks, Leo M.A.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - In congestive heart failure (CHF), diaphragm weakness is known to occur and is associated with myosin loss and activation of the ubiquitin-proteasome pathway. The effect of modulating proteasome activity on myosin loss and diaphragm function is unknown. The present study investigated the effect of in vivo proteasome inhibition on myosin loss and diaphragm function in CHF rats. Coronary artery ligation was used as an animal model for CHF. Sham-operated rats served as controls. Animals were treated with the proteasome inhibitor bortezomib (intravenously) or received saline (0.9%) injections. Force generating capacity, cross-bridge cycling kinetics, and myosin content were measured in diaphragm single fibers. Proteasome activity, caspase-3 activity, and MuRF-1 and MAFbx mRNA levels were determined in diaphragm homogenates. Proteasome activities in the diaphragm were significantly reduced by bortezomib. Bortezomib treatment significantly improved diaphragm single fiber force generating capacity (∼30-40%) and cross-bridge cycling kinetics (∼20%) in CHF. Myosin content was ∼30% higher in diaphragm fibers from bortezomib-treated CHF rats than saline. Caspase-3 activity was decreased in diaphragm homogenates from bortezomib-treated rats. CHF increased MuRF-1 and MAFbx mRNA expression in the diaphragm, and bortezomib treatment diminished this rise. The present study demonstrates that treatment with a clinically used proteasome inhibitor improves diaphragm function by restoring myosin content in CHF.

AB - In congestive heart failure (CHF), diaphragm weakness is known to occur and is associated with myosin loss and activation of the ubiquitin-proteasome pathway. The effect of modulating proteasome activity on myosin loss and diaphragm function is unknown. The present study investigated the effect of in vivo proteasome inhibition on myosin loss and diaphragm function in CHF rats. Coronary artery ligation was used as an animal model for CHF. Sham-operated rats served as controls. Animals were treated with the proteasome inhibitor bortezomib (intravenously) or received saline (0.9%) injections. Force generating capacity, cross-bridge cycling kinetics, and myosin content were measured in diaphragm single fibers. Proteasome activity, caspase-3 activity, and MuRF-1 and MAFbx mRNA levels were determined in diaphragm homogenates. Proteasome activities in the diaphragm were significantly reduced by bortezomib. Bortezomib treatment significantly improved diaphragm single fiber force generating capacity (∼30-40%) and cross-bridge cycling kinetics (∼20%) in CHF. Myosin content was ∼30% higher in diaphragm fibers from bortezomib-treated CHF rats than saline. Caspase-3 activity was decreased in diaphragm homogenates from bortezomib-treated rats. CHF increased MuRF-1 and MAFbx mRNA expression in the diaphragm, and bortezomib treatment diminished this rise. The present study demonstrates that treatment with a clinically used proteasome inhibitor improves diaphragm function by restoring myosin content in CHF.

KW - Bortezomib

KW - Myosin

KW - Single fiber contractility

UR - http://www.scopus.com/inward/record.url?scp=48949119350&partnerID=8YFLogxK

U2 - 10.1152/ajplung.00035.2008

DO - 10.1152/ajplung.00035.2008

M3 - Article

VL - 294

JO - American Journal of Physiology. Lung Cellular and Molecular Physiology

JF - American Journal of Physiology. Lung Cellular and Molecular Physiology

SN - 1040-0605

IS - 6

ER -